Action. Indications. Dos age and Adminis tration

Similar documents
CLINICAL PHARMACOLOGY

INDICATIONS AND USAGE SULFAMYLON Cream is a topical agent indicated for adjunctive therapy of patients with second- and third- degree burns.

BAYER ADVANCED ASPIRIN REGULAR STRENGTH-

HYDROCORTISONE OINTMENT USP,

July 2018 JMLA Appendix A Hunter et al., dx.doi.org/ /jmla

ELESTAT- epinastine hydrochloride solution/ drops Allergan, Inc

Active drug ingredient Chlortetracycline calcium complex equivalent to 50 g chlortetracycline hydrochloride per lb.

CLINICAL PHARMACOLOGY

chew 2 tablets daily; not more than 2 tablet in 24 hours chew 1 tablet daily; not more than 1 ask a doctor

DESCRIPTION: Each gram of ointment contains 500 units of Bacitracin in a low melting special base containing White Petrolatum and Mineral Oil.

CLINICAL PHARMACOLOGY

BETHANECHOL CHLORIDE- bethanechol chloride tablet Ris ing Pharmaceuticals Inc Bethanechol Chloride Tablets USP

DECALCITROL- cholecalciferol tablet, coated Pharmin USA, LLC DECALCITROL CHOLECALCIFEROL (VITAMIN D3) 1.25 mg TABLETS (50,000 Units)

Warnings Allergy alert: Ibuprofen may cause a severe allergic reaction, especially in people allergic to aspirin. Symptoms may include:

DESCRIPTION Sodium tetradecyl sulfate is an anionic surfactant which occurs as a white, waxy solid. The structural formula is as follows:

PILOCARPINE HYDROCHLORIDE- pilocarpine hydrochloride solution Falcon Pharmaceuticals, Ltd

Tranexamic acid, USP is a white crystalline powder. The aqueous solution for injection has a ph of 6.5 to 8.0.

CLINICAL PHARMACOLOGY

FLUOCINOLONE ACETONIDE-

Molecular Formula: C9 H13 NO 2 HCl Molecular Weig ht:

CLINICAL PHARMACOLOGY

Each gram of the ointment contains 0.25 mg Fluocinolone Acetonide in a base containing White Petrolatum.

APRACLONIDINE OPHTHALMIC-

BROMFENAC- bromfenac solution/ drops Hi-Tech Pharmacal Co., Inc

Concentration 0.5% 1% 1.5% 2% mg/ml lidocaine HCl (anhyd.) mg/ml sodium chloride

Each caps ule contains Vitamin D (Ergocalciferol) 1.25 mg equivalent to 50,000 USP Units.

BUTALBITAL, ACETAMINOPHEN, AND CAFFEINE-

Caution Federal law restricts this drug to use by or on the order of a licensed veterinarian.

CLINICAL PHARMACOLOGY

HYDROXYPROGESTERONE CAPROATE- hydroxyprogesterone caproate injection ANI Pharmaceuticals, Inc Hydroxyproges terone Caproate Injection USP

O HCl Molecular Weig ht:

DESCRIPTION HydrOXYzine hydrochloride has the chemical name of 2-[2-[4-(p-Chloro- -phenylbenzyl)-1- piperazinyl] ethoxy] ethanol dihydrochloride.

CLINICAL PHARMACOLOGY Like other topical corticosteroids, clobetasol propionate has anti-inflammatory, antipruritic, and

CLINICAL PHARMACOLOGY

RESTASIS- cyclosporine emulsion Allergan, Inc

Potassium chloride injection (approximately diluted) is a parenteral fluid and electrolyte replenisher.

CLOBETASOL PROPIONATE-

Prednisolone Sodium Phosphate Ophthalmic Solution USP, 1% (Sterile) Rx only

CLINICAL PHARMACOLOGY

GLOFIL-125- sodium iothalamate i-125 injection injection, solution Is o-tex Diagnos tics, Inc Glofil-125 R

NEOSPORIN Ophthalmic Solution Sterile (neomycin and polymyxin B sulfates and gramicidin ophthalmic solution, USP)

The molecular formula of timolol is Formula C H N O S and its structural formula is:

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE-

DICLOXACILLIN SODIUM-

CLINICAL PHARMACOLOGY:

GLIPIZIDE- glipizide tablet, film coated, extended release Ris ing Pharmaceuticals, Inc

CHLORTHALIDONE- chlorthalidone tablet Ris ing Pharmaceuticals, Inc CHLORTHALIDONE TABLETS USP, 25 mg and 50 mg

CLINICAL PHARMACOLOGY

LIDOCAINE HYDROCHLORIDE TOPICAL SOLUTION USP 4%

LEVOLEUCOVORIN CALCIUM- levoleucovorin injection, solution Mylan Ins titutional LLC

3 DOSAGE FORMS AND STRENGTHS

BIMATOPROST- bimatoprost solution/ drops Apotex Corp

OXACILLIN - oxacillin sodium injection, powder, for solution. AuroMedics Pharma LLC OXACILLIN FOR INJECTION, USP Rx only

DIAZEPAM- diazepam gel Teva Pharmaceuticals USA Inc Diazepam Rectal Gel CIV Rectal Delivery Sys tem Rx Only

CLINICAL PHARMACOLOGY

LYSOBACT COMPLETE SPRAY ( ) mg / ml Oromucosal spray, solution

BETOPTIC S - betaxolol hydrochloride suspension/ drops Alcon Laboratories, Inc

TABLE 1 Principal Radiation Emission Data Radiation Mean % per Disintegration Mean Energy (kev) Gamma

DOSAGE AND ADMINISTRATION.) DESCRIPTION

Draft Labeling Package Insert Not Actual Size. BRAINTREE LABORATORIES, INC. PhosLo Capsules (Calcium Acetate)

PYTEST- urea, c-14 capsule Avent, Inc Des cription

Dentsply. Citanest Plain 4% Box of 50. Citanest Forte 4% Prilocaine HCl Epinephrine 1:200,000 EPI. Box of 50. Xylocaine 2% Red 50/pkg 1:100,000 EPI

LOTEMAX- loteprednol etabonate gel Baus ch & Lomb Incorporated

LOTEMAX- loteprednol etabonate ointment Baus ch & Lomb Incorporated

GRANISETRON- granisetron hydrochloride injection Sandoz Inc

DIAZEPAM- diazepam tablet IVAX Pharmaceuticals, Inc DIAZEPAM TABLETS USP CIV

INVELTYS- loteprednol etabonate suspension Kala Pharmaceuticals, Inc

Naloxone Standardized Procedures Illinois Departments of DFPR, DPH & DHS Opioid Antagonist Initiative

LIDOCAINE- lidocaine ointment VITRUVIAS THERAPEUTICS Lidocaine Ointment USP, 5% For topical us e only Do not use in the eyes Rx Only

NEOSPORIN G.U. Irrigant Sterile (neomycin sulfate polymyxin B sulfate solution for irrigation)

Mepivacaine Hydrochloride Injection USP, 3%

For the list of inactive ingredients see section "Additional information".

NEOPROFEN - ibuprofen lysine solution RECORDATI RARE DISEASES, INC

Overview. Normally, the process is completely reversible.

Core Safety Profile. Pharmaceutical form(s)/strength: solution 1%, spray 1%, cream 1%, gel 1% SK/H/PSUR/0005/001 Date of FAR:

BAYER: KOGENATE FS WITH BIOSET (Recombinant FVIII)

Calcium Folinate Solution for Injection

LEUCOVORIN CALCIUM - leucovorin calciumâ tabletâ Barr Laboratories Inc LEUCOVORIN CALCIUM TABLETS USP Â Rx only

Package leaflet: Information for the patient. / / 30 mg/5 ml syrup. Ambroxol hydrochloride

CONTRAINDICATIONS None.

DESCRIPTION: Nitroglycerin is 1,2,3-propanetriol trinitrate, an organic nitrate whose structural formula is:

NEW ZEALAND DATA SHEET

NEOSPORIN Ophthalmic Solution Sterile (neomycin and polymyxin B sulfates and gramicidin ophthalmic solution, USP)

ESKATA TM (hydrogen peroxide) topical solution Initial U.S. Approval: 2017

HIGHLIGHTS OF PRESCRIBING INFORMATION

PARACOD Tablets (Paracetamol + Codeine phosphate)

TAFEN NASAL 50mcg nasal spray, suspension

PHARMACY BULK PACKAGE NOT FOR DIRECT INFUSION FOR INTRAVENOUS INFUSION ONLY. MUST BE DILUTED PRIOR TO INJECTION.

Pfizer, BeneFIX R2 Recombinant Factor IX

PRESCRIBING INFORMATION WITH CONSUMER INFORMATION MYDRIACYL. tropicamide ophthalmic solution, USP. 0.5% and 1% w/v.

DRAXIMAGE MDP-25 Kit for the Preparation of Technetium Tc 99m Medronate Injection. For Intravenous Use DIAGNOSTIC FOR SKELETAL IMAGING

PHARMACY COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 11/16/17 SECTION: DRUGS LAST REVIEW DATE: 11/16/17 LAST CRITERIA REVISION DATE: ARCHIVE DATE:

Chemical Name: 4H-Pyrano[3,2-g]quinoline-2,8-dicarboxylic acid, 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-, disodium salt.

CERETEC- technetium tc-99m exametazime and cobaltous chloride Medi-Phys ics, Inc. dba GE Healthcare

Indications and Usage: For determining cardiac output, hepatic function and liver blood flow, and for ophthalmic angiography.

CYTARABINE- cytarabine injection Mylan Ins titutional LLC Cytarabine Injection

CAUTION Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

PULMOZYME- dornase alfa solution Genentech, Inc Pulmozyme (dornas e alfa) Inhalation Solution

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Transcription:

CETACAINE ANESTHETIC- benzocaine, butamben and tetracaine hydrochloride aeros ol, spray Cetylite Indus tries, Inc. Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here. ---------- Cetacaine Topical Anes thetic Action The onset of Cetacaine-produced anesthesia is rapid (approximately 30 seconds) and the duration of anesthesia is typically 30-60 minutes, when used as directed. This effect is due to the rapid onset, but short duration of action of Benzocaine coupled with the slow onset, but extended duration of Tetracaine HCI and bridged by the intermediate action of Butamben. It is believed that all of these agents act by reversibly blocking nerve conduction. Speed and duration of action is determined by the ability of the agent to be absorbed by the mucous membrane and nerve sheath and then to diffuse out, and ultimately be metabolized (primarily by plasma cholinesterases) to inert metabolites which are excreted in the urine. Indications Cetacaine is a topical anesthetic indicated for the production of anesthesia of all accessible mucous membrane except the eyes. Cetacaine Spray is indicated for use to control pain or gagging. Cetacaine in all forms is indicated to control pain and for use for surgical or endoscopic or other procedures in the ear, nose, mouth, pharynx, larynx, trachea, bronchi, and esophagus. It may also be used for vaginal or rectal procedures when feasible. Dos age and Adminis tration Cetacaine Spray should be applied for approximately one second or less for normal anesthesia. Only a limited quantity of Cetacaine is required for anesthesia. Spray in excess of two seconds is contraindicated. Average expulsion rate of residue from spray, at normal temperatures, is 200 mg per second. To apply, insert the Jetco cannula (J-4) firmly onto the protruding plastic stem on the bottle and press the cannula forward to actuate the spray valve. The cannula may be removed and reinserted as many times as required for cleaning, or sterilization, and is autoclavable.

Cetacaine Liquid Apply 200 mg (approximately 6 7 drops or 0.2 cc) with a cotton applicator or directly to tissue. Do not hold the cotton applicator in position for extended periods of time, since local reactions to benzoate topical anesthetics are related to the length of time of application. Liquid in excess of 400 mg (approx. 2 4 drops or 0.4 cc) is contraindicated. *See Cetacaine Liquid Kit instructions for additional directions for application by Luer-lock syringe and applicator tip. Cetacaine Gel Apply 200 mg of gel (a bead approximately 0.5 inch (3 mm) in length and 3/6 inch (5 mm) in diameter) and spread thinly and evenly over the application area. Gel in excess of 400 mg (a bead approximately inch (26 mm) in length and 3/6 inch (5 mm) in diameter) is contraindicated. An appropriate pediatric dosage has not been established for Cetacaine Spray, Liquid or Gel. Dosages should be reduced in the debilitated elderly, acutely ill, and very young patients. Tissue need not be dried prior to application of Cetacaine. Cetacaine should be applied directly to the site where pain control is required. Anesthesia is produced within one minute with an approximate duration of thirty minutes. Each 200 mg dose of Cetacaine (Spray residue, Liquid or Gel) contains 28 mg of benzocaine, 4 mg of butamben and 4 mg of tetracaine HCl. Advers e Reactions Hypers ens itivity Reactions: Unpredictable adverse reactions (i.e. hypersensitivity, including anaphylaxis) are extremely rare. Localized allergic reactions may occur after prolonged or repeated use of any aminobenzoate anesthetic. The most common adverse reaction caused by local anesthetics is contact dermatitis characterized by erythema and pruritus that may progress to vesiculation and oozing. This occurs most commonly in patients following prolonged self-medication, which is contraindicated. If rash, urticaria, edema, or other manifestations of allergy develop during use, the drug should be discontinued. To minimize the possibility of a serious allergic reaction, Cetacaine preparations should not be applied for prolonged periods except under continual supervision. Dehydration of the epithelium or an escharotic effect may also result from prolonged contact. Precaution: On rare occasions, methemoglobinemia has been reported in connection with the use of benzocaine-containing products. Care should be used not to exceed the maximum recommended dosage (see Dosage and Administration). If a patient becomes cyanotic, treat appropriately to counteract (such as with methylene blue, if medically indicated). Use in Pregnancy Safe use of Cetacaine has not been established with respect to possible adverse effects upon fetal development. Therefore, Cetacaine should not be used during early pregnancy, unless

in the judgment of a physician, the potential benefits outweigh the unknown hazards. Routine precaution for the use of any topical anesthetic should be observed when Cetacaine is used. Cetacaine is not suitable and should never be used for injection. Do not use on the eyes. To avoid excessive systemic absorption, Cetacaine should not be applied to large areas of denuded or inflamed tissue. Cetacaine should not be administered to patients who are hypersensitive to any of its ingredients or to patients known to have cholinesterase deficiencies. Tolerance may vary with the status of the patient. Cetacaine should not be used under dentures or cotton rolls, as retention of the active ingredients under a denture or cotton roll could possibly cause an escharotic effect. Routine precaution for the use of any topical anesthetic should be observed when using Cetacaine. Jetco Cannula for Cetacaine Spray The supplied 4" stainless steel Jetco cannula (J-4) for Cetacaine Spray is specially designed for accessibility and application of Cetacaine, at the required site of pain control. Replacement J-4 cannulas are available as a 0-pack (Item # 0205). How Supplied Cetacaine Spray, 56 g bottle, including propellant* (Item # 020, NDC 0223-020-) which includes one J-4 cannula. Cetacaine Gel, 32 g pump jar, (Item # 027, NDC 0223-027-3) Cetacaine Liquid Chairside Kit (Item # 028 NDC 0223-0202-6) which includes one 4 g bottle of Cetacaine Liquid with Luer-lock dispenser cap, 20 syringes and 20 delivery tips. Cetacaine Liquid Clinical Kit (Item # 022, NDC 0223-0202-5) which includes one 30 g bottle of Cetacaine Liquid with Luer-lock dispenser cap, 00 syringes and 00 delivery tips. Cetacaine Liquid, 4 g bottle (Item # 0203, NDC 0223-0202-2) Cetacaine Liquid, 30 g bottle (Item # 02, NDC 0223-0202-4) Cetacaine Spray contains CFC-4 and CFC-, s ubs tances which harm public health and environment by des troying ozone in the upper atmosphere. RX Only.

Cetacaine Spray Box CETACAINE ANESTHETIC benzocaine, butamben, and tetracaine hydrochloride aerosol, spray Product Information Product T ype HUMAN PRESCRIPTION DRUG Ite m Code (Source ) NDC:0 223-0 20 Route of Administration TOPICAL DEA Sche dule Active Ing redient/active Moiety Ing redient Name Basis o f Streng th Streng th Benzo ca ine (UNII: U3RSY48 JW5) (Benzo caine - UNII:U3RSY48 JW5) Benzo caine 0.0 28 g in 0.2 g Buta mben (UNII: EFW8 578 72Q) (Butamben - UNII:EFW8 578 72Q) Butamben 0.0 0 4 g in 0.2 g Tetra ca ine Hydro chlo ride (UNII: 5NF5D4OPCI) (Tetracaine - UNII:0 6 9 F35CGV) Tetracaine Hydro chlo ride 0.0 0 4 g in 0.2 g Inactive Ing redients Ing redient Name Dipro pylene g lyco l (UNII: E0 7L8 5C40 ) Sa ccha rin (UNII: FST46 7XS7D) Benza lko nium chlo ride (UNII: F5UM2KM3W7) Mecetro nium bro mide (UNII: 7ZNQ7FIO9 K) Streng th Product Characteristics

Color Score Shape Siz e Flavor BANANA Imp rint Cod e Contains Packag ing # Item Co de Packag e Descriptio n NDC:0 223-0 20 - in BOX 56 g in BOTTLE, GLASS; Type 0 : No t a Co mbinatio n Pro duct Marketing Start Date Marketing End Date Marketing Information Marke ting Cate gory Application Numbe r or Monograph Citation Marke ting Start Date Marke ting End Date UNAPPROVED DRUG OTHER 0 /0 /9 58 Labeler - Cetylite Indus tries, Inc. (00283704) Establishment Name Addre ss ID/FEI Busine ss Ope rations Cetylite Industries, Inc. 0 0 28 370 4 MANUFACTURE(0 223-0 20 ), ANALYSIS(0 223-0 20 ), LABEL(0 223-0 20 ), PACK(0 223-0 20 ) Revised: 8/204 Cetylite Industries, Inc.